Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aceso Life Science GroupHKSE:00474 -1.35%19 3-Year ROIIC % is 0.76 as of Mar. 2026, which is 31% below its 10-year median of 1.10. GuruFocus rates HKSE:00474 with a GF Score™ of 19/100 and a GF Value™ of HK$0.03 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,007 Business Services companies, Aceso Life Science Group ranks worse than 61.27% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Aceso Life Science Group's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was 0.76%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Aceso Life Science Group's 3-Year ROIIC % or its related term are showing as below:
HKSE:00474's 3-Year ROIIC % is ranked worse than 61.27% of 1007
companies
in the Business Services industry
Industry Median: 5.46
vs HKSE:00474: 0.76
Aceso Life Science Group (HKSE:00474) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Aceso Life Science Group 3-Year ROIIC % Related Terms
Aceso Life Science Group 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:00474 vs URI, SUNB, AER: 3-Year ROIIC % Comparison
For the Rental & Leasing Services subindustry, Aceso Life Science Group's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aceso Life Science Group 3-Year ROIIC % vs Business Services Industry
For the Business Services industry and Industrials sector, Aceso Life Science Group's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Aceso Life Science Group's 3-Year ROIIC % falls into.
Aceso Life Science Group 3-Year ROIIC % Calculation
Aceso Life Science Group's 3-Year ROIIC % for the quarter that ended in Mar. 2026 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -23 (Mar. 2026) - 15.624 (Mar. 2023) )
/
( 1437 (Mar. 2026) - 6529 (Mar. 2023) )
=
-38.624
/
-5092
=
0.76%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Aceso Life Science Group (HKSE:00474) has a 3-Year ROIIC % of 0.76 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Aceso Life Science Group and its competitors. This is 31% below median its historical median of 1.10. According to the industry distribution chart, Aceso Life Science Group ranks #617 out of 1007 companies in the Business Services industry, placing it in the top 61.3%.
Is Aceso Life Science Group's 3-Year ROIIC % too high?
Aceso Life Science Group's current 3-Year ROIIC % of 0.76 is 31% below median its 10-year median of 1.10. The Business Services industry median 3-Year ROIIC % is 5.46. Aceso Life Science Group's value of 0.76 is 86.1% below this industry median. Based on the distribution chart, Aceso Life Science Group ranks #617 out of 1007 companies in the Business Services industry, which is below the industry midpoint. Overall, Aceso Life Science Group has a GF Score™ of 19/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aceso Life Science Group's 3-Year ROIIC % compare to URI and SUNB?
According to the Business Services industry distribution chart, Aceso Life Science Group ranks #617 out of 1007 companies for 3-Year ROIIC %. This places Aceso Life Science Group in the lower half of its industry. The industry median 3-Year ROIIC % is 5.46. Aceso Life Science Group's value of 0.76 is 86.1% below this benchmark. While the company's 10-year median is 1.10 vs. the industry median of 5.46, Aceso Life Science Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Business Services company?
The median 3-Year ROIIC % among Business Services companies is 5.46, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aceso Life Science Group's current 3-Year ROIIC % of 0.76 is 86.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Aceso Life Science Group and its competitors. For the Business Services industry, the median 3-Year ROIIC % is 5.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aceso Life Science Group's current 3-Year ROIIC % is 0.76, which is 31% below median its own 10-year median of 1.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aceso Life Science Group stock overvalued right now?
Based on GuruFocus' analysis, Aceso Life Science Group (HKSE:00474) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.03, compared to a current price of HK$0.15 — trading 386.7% above its estimated fair value. The current 3-Year ROIIC % is 0.76, which is 31% below median its 10-year median of 1.10 and 86.1% below the Business Services industry median of 5.46. Aceso Life Science Group's overall GF Score™ is 19/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Aceso Life Science Group (HKSE:00474), the current 3-Year ROIIC % is 0.76 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aceso Life Science Group (HKSE:00474) Overvalued in 2026?
Based on GuruFocus' analysis, Aceso Life Science Group stock appears to be overvalued.
The current stock price of HK$0.15 is trading 386.7% above its estimated GF Value™ of HK$0.03.
GuruFocus considers Aceso Life Science Group to be Significantly Overvalued.
Key valuation signals for HKSE:00474:
3-Year ROIIC %: 0.76 (31% below median its 10-year median of 1.10)
GF Value™: HK$0.03 vs. price of HK$0.15 (386.7% above fair value)
Industry Position: 86.1% below the Business Services median (#617 of 1007)
No single metric tells the full story. See the HKSE:00474 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aceso Life Science Group Ltd is an investment holding company. The group's operating segments include Money lending, Rental and sale of construction machinery and spare parts business, Provision of repair and maintenance and transportation service business, Provision of asset management, securities brokerage, commodities, futures, and other financial service business, Property leasing business, and Property development business. It derives key revenue from the rental and sale of construction machinery and spare parts. Geographically, the group has a business presence in Hong Kong, the UK, the PRC, Macau, and Cambodia.
19GF Score
Get the complete analysis for HKSE:00474
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00474 has been successfully added to your 
